Amylyx Pharmaceuticals Financials
| AMLX Etf | USD 3.60 0.10 2.86% |
Operating Margin | Profit Margin | Short Ratio 2.64 | EPS Estimate Current Year (4.29) | EPS Estimate Current Quarter (0.71) |
Amylyx |
The data published in Amylyx Pharmaceuticals' official financial statements typically reflect Amylyx Pharmaceuticals' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Amylyx Pharmaceuticals' quantitative information. For example, before you start analyzing numbers published by Amylyx accountants, it's essential to understand Amylyx Pharmaceuticals' liquidity, profitability, and earnings quality within the context of the Pharmaceuticals space in which it operates.
Please note, the imprecision that can be found in Amylyx Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amylyx Pharmaceuticals. Check Amylyx Pharmaceuticals' Beneish M Score to see the likelihood of Amylyx Pharmaceuticals' management manipulating its earnings.
Amylyx Pharmaceuticals Etf Summary
Amylyx Pharmaceuticals competes with Terns Pharmaceuticals, Acumen Pharmaceuticals, Inozyme Pharma, X4 Pharmaceuticals, and Day One. Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Etf View All |
| Exchange | NASDAQ Exchange |
| ISIN | US0321085088 |
| CUSIP | 03237H101 |
| Region | Others |
| Investment Issuer | Others |
| Location | Massachusetts; U.S.A |
| Business Address | 43 Thorndike Street, |
| Etf Family | Pharmaceuticals |
| Fund Category | Others |
| Portfolio Concentration | Others |
| Benchmark | Dow Jones Industrial |
| Website | amylyx.com |
| Phone | 617 682 0917 |
| Currency | USD - US Dollar |
Amylyx Pharmaceuticals Key Financial Ratios
Amylyx Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Amylyx Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Amylyx Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amylyx Pharmaceuticals competition to find correlations between indicators driving Amylyx Pharmaceuticals's intrinsic value. More Info.Amylyx Pharmaceuticals is fourth largest ETF in price to book as compared to similar ETFs. It is rated below average in price to sales as compared to similar ETFs fabricating about 1.00 of Price To Sales per Price To Book. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amylyx Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Amylyx Pharmaceuticals Systematic Risk
Amylyx Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Amylyx Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Amylyx Pharmaceuticals correlated with the market. If Beta is less than 0 Amylyx Pharmaceuticals generally moves in the opposite direction as compared to the market. If Amylyx Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Amylyx Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Amylyx Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Amylyx Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Amylyx Pharmaceuticals January 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Amylyx Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Amylyx Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Amylyx Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Amylyx Etf price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Amylyx Pharmaceuticals's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.49 | |||
| Information Ratio | 0.0243 | |||
| Maximum Drawdown | 33.56 | |||
| Value At Risk | (8.97) | |||
| Potential Upside | 9.49 |
Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.